A bias related to the shorter follow-up of patients with HER2-positive BC treated with trastuzumab also explains why, according to Kaplan-Meier curves (Figure 4), the 10-year DFS and OS of ER+/PR±/HER2- BC patients seems worse than ER+/PR±/HER2+. The gene discussed is ERBB2; the disease is breast cancer.